Skip to main content
Medical information Clinical review pending

Genetic Testing

RINT1 Gene Breast Cancer RINT1 Related Genetic Test

The RINT1 Gene Breast Cancer test uses Next-Generation Sequencing (NGS) to analyze genetic variations in the RINT1 gene, which may be linked to an increased risk of breast cancer. This test provides valuable insights for proactive health management.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube), extracted DNA, or FTA card.
Results
Approximately 3 to 4 weeks. Confirm with the laboratory before booking.
Preparation
A clinical history review by a healthcare provider is required. A genetic counseling session is recommended to create a pedigree chart of family members affected by breast cancer. Confirm with the laboratory before booking.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the RINT1 Gene Breast Cancer RINT1 Related Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Personal history of breast cancer
  • ✓Family history of breast cancer
  • ✓Individuals considering prophylactic surgery
  • ✓Genetic counseling for risk assessment
  • ✓Early detection of genetic predisposition
02

In plain language

What this test helps you understand

Identifies genetic variations in the RINT1 gene associated with increased breast cancer risk, aiding in risk assessment and personalized prevention strategies.
The RINT1 Gene Breast Cancer test is a diagnostic tool designed to identify genetic mutations associated with an increased risk of breast cancer. This test employs Next-Generation Sequencing (NGS) technology to provide comprehensive insights into your genetic makeup, allowing for early detection and preventive measures.

This test specifically measures variations in the RINT1 gene, which has been linked to breast cancer susceptibility. By analyzing the genetic code, healthcare providers can determine if an individual carries mutations that may elevate their risk of developing breast cancer.

Individuals with a family history of breast cancer or those who exhibit symptoms such as unusual lumps or changes in breast tissue should consider this test. Additionally, patients with known risk factors, including age, personal medical history, and certain genetic backgrounds, may benefit from early genetic screening.

Benefits of taking the test include early detection of genetic predispositions to breast cancer, informed decision-making regarding preventive measures and treatment options, personalized healthcare management based on genetic insights, and access to genetic counseling for better understanding and support.

Your test results will indicate whether you have any mutations in the RINT1 gene. A genetic counselor will provide guidance on interpreting these results and discussing potential next steps, which may include increased surveillance or preventive strategies.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationA clinical history review by a healthcare provider is required. A genetic counseling session is recommended to create a pedigree chart of family members affected by breast cancer. Confirm with the laboratory before booking.
SampleBlood sample (EDTA tube), extracted DNA, or FTA card.
MethodologyNext-Generation Sequencing (NGS)
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test analyzes only the RINT1 gene. It does not assess risk associated with other genes linked to breast cancer. A negative result does not eliminate the risk of developing breast cancer. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

The RINT1 gene is a gene that researchers have linked to an increased risk of developing breast cancer in some individuals.
Individuals with a personal or family history of breast cancer, or those with other risk factors, may be candidates for this test. Discuss with your doctor.
Results indicate the presence or absence of specific variations in the RINT1 gene. A genetic counselor will help interpret the results and discuss implications.
Genetic counseling is recommended to understand the test and its results, but it may be arranged separately. Confirm with the laboratory before booking.
A sample can be collected via a blood draw, using extracted DNA, or a single drop of blood on an FTA card.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp